The agenda for the 7 January 2015 Transparency Commission meeting is now available. The Commission will consider the following medicines:

• Ranibizumab (Lucentis) - review of SMR & ASMR
• Ataluren (Translarna) - new medicine
• Ivabradine hydrochloride (Procoralan) - review of SMR & ASMR
• (Topiscab) - new medicine
• Ponatinib hydrochloride (Iclusig) - new medicine
• Omalizumab (Xolair) - new indication
• Vinflunine tartrate (Javlor) - reassessment
• Vedolizumab (Entyvio) - reassessment
• Misoprostol (Misodel) - reassessment

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-12/odj_ct_07012015_internet.pdf